

Central Lancashire Online Knowledge (CLOK)

Title	Vibrational spectroscopy: a promising approach to discriminate neurodegenerative disorders
Type	Article
URL	https://clock.uclan.ac.uk/id/eprint/22730/
DOI	https://doi.org/10.1186/s13024-018-0252-x
Date	2018
Citation	Paraskevaidi, Maria, Martin-Hirsch, Pierre L and Martin, Francis L (2018) Vibrational spectroscopy: a promising approach to discriminate neurodegenerative disorders. <i>Molecular Neurodegeneration</i> , 13 (20). ISSN 1750-1326
Creators	Paraskevaidi, Maria, Martin-Hirsch, Pierre L and Martin, Francis L

It is advisable to refer to the publisher's version if you intend to cite from the work.
<https://doi.org/10.1186/s13024-018-0252-x>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLOK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

COMMENTARY

Open Access



Vibrational spectroscopy: a promising approach to discriminate neurodegenerative disorders

Maria Paraskevaïdi^{1*} , Pierre L. Martin-Hirsch² and Francis L. Martin^{1*}

Abstract

Neurodegenerative diseases are a growing burden in modern society, thus crucially calling for the development of accurate diagnostic strategies. These diseases are currently incurable, a fact which has been attributed to their late diagnosis, after brain damage has already become widespread. An earlier and improved diagnosis is necessary for the enrolment of patients into clinical trials and can pave the way for the development of therapeutic tactics. Novel analytical techniques, such as mass spectrometry and vibrational spectroscopy, have been able to successfully detect and characterise neurodegenerative disorders. It is critical to globally support and make use of innovative basic research and techniques, which could ultimately lead to the creation of a cost-effective diagnostic test. Minimally invasive samples, such as biological fluids, have also been shown to reveal information for these diseases; utilising them could simplify sample collection/analysis and be more preferable to patients.

Keywords: Infrared spectroscopy, Raman spectroscopy, Neurodegenerative disease, Diagnosis

Background

In recent years, research has made great strides in deciphering the underlying mechanisms of neurodegenerative diseases. It is now widely accepted that brain changes associated with the disease commence years prior to symptomatology, when preventative / therapeutic strategies are more likely to successfully intervene and decelerate, if not cease, disease progression. The fact that neurodegeneration is a slowly progressive disease can allow enough time for a series of screening tests and potentially a timely diagnosis to be made. Nonetheless, currently a definitive diagnosis can only be provided post-mortem and a robust means for early diagnosis remains yet to be established.

Main text

As the percentage of the population over 65 years is growing, so is the burden of neurodegenerative disorders. An estimated 50 million people worldwide live with dementia, with this number getting doubled every 20 years, expected to reach 75 million in 2030 and 131.5 million in 2050 [1].

The major and enduring healthcare costs for neurodegenerative disease sufferers and their families are prohibitive in many countries and their respective health systems. For instance, the worldwide economic burden of dementia patients alone has been estimated to rise above a US\$ trillion. It is evident that an accurate and cost-effective screening approach could permit the development of early preventative strategies that could impact on the disease progression.

Two decades ago, the first evidence of the structure of β -amyloid plaques was revealed by synchrotron infrared (IR) microspectroscopy, after in situ analysis of the brain of an Alzheimer's disease patient [2]. Today, technological improvements and new techniques, such as mass spectrometry or vibrational and nuclear magnetic resonance spectroscopies, have emerged as promising detection tools in the field of neurodegeneration [3–6]. Vibrational spectroscopy, including IR and Raman, is by far the simplest method, requiring less sophisticated instrumentation and consumables, thus automatically decreasing the expenses and rendering a potential test easily translatable (Fig. 1). So far, numerous studies have demonstrated the efficacy of vibrational spectroscopy in identifying individuals with various degenerative conditions, such as dementia or Parkinson's disease, with high levels of diagnostic accuracy [7, 8].

* Correspondence: mparaskevaïdi@uclan.ac.uk; flmartin@uclan.ac.uk

¹School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK

Full list of author information is available at the end of the article






Fig. 1 The potential of biospectroscopy in a clinical diagnostic pathway. **a** A handheld device is used to analyse the sample (e.g., blood or CSF) causing vibrations to its molecules. **b** Infrared and **(c)** Raman spectroscopies generate characteristic spectra which allow the identification of biomarkers indicative of disease. **d** Spectral analysis then follows to classify the patients into different categories using a traffic-light system: red suggesting disease, amber proposing high risk and further investigation and green indicate absence of disease

Previous research has focused on the development of panels of biomarkers to improve the diagnostic accuracy for neurodegenerative diseases. However, the majority of the employed techniques require either expensive or invasive and laborious methods, including imaging and cerebrospinal fluid testing. In contrast, vibrational spectroscopy has the ability to investigate and identify numerous biological molecules simultaneously, therefore providing a multiple marker test for an underlying pathology while being rapid and inexpensive. Using developed machine-learning algorithms, the system is “trained” to recognize unique spectral markers that indicate disease; thus, when unknown samples are introduced, it is possible to accurately assess them in a traffic-light manner, with amber and red light suggesting further investigation and disease, respectively, while a green light would indicate absence of disease. Accordingly, high-risk population, as well as people with mild cognitive impairment or a traumatic brain injury could be monitored by serial sampling, which can be easily achieved by minimally-invasive blood tests. A detection of brain changes early in the course of disease would allow individuals to enroll in potential clinical trials, therefore promoting drug development and benefiting patients. An important advantage of this traffic-light system is that there is no need for prior expertise in spectroscopy and spectral analysis, with a nurse or a clinical doctor being able to immediately interpret the result. A representative example

is the use of Raman spectroscopy during brain cancer surgery, which can provide invaluable information to surgeons by defining surgical margins in patients with different grades of brain tumour severity [9].

Conclusions

Spectroscopy of biological fluids, such as blood and cerebrospinal fluid, is anticipated to facilitate the development of novel, cost-effective diagnostic strategies and promote rapid primary care. Recently developed hand-held portable devices also facilitate point-of-care diagnostics which could significantly expedite clinical implementation. Use of such technologies could enhance the accuracy of neurological diagnosis and also categorize disease types. However, similar to any innovation pending translation in a clinical context, spectroscopy requires a series of validation steps, including large-scale studies and coordinated efforts across different, multidisciplinary research groups. Both scientific and clinical communities need to embrace non-traditional methodologies and redouble their efforts towards the repetition and validation of the latter in order to render them translatable in a clinical context. A vital step for success would be to share knowledge and research results in wide-ranging and free-access electronic platforms from where patients, researchers and doctors alike would be able to keep track with the latest advancements in the area of neurodegeneration.

Abbreviations

IR: infrared

Acknowledgements

MP would like to thank Rosemere Cancer Foundation for funding.

Funding

Rosemere Cancer Foundation has provided funding for MP.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Authors' contributions

MP wrote the manuscript; PLMH and FLM provided constructive feedback and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Competing interests

Authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK. ²Lancashire Teaching Hospitals NHS Foundation, Sharoe Green Unit, Fullwood, Preston PR2 9HT, UK.

Received: 9 April 2018 Accepted: 24 April 2018

Published online: 02 May 2018

References

1. Martin P, Anders W, Maëlen G, Gemma-Claire A, Yu-Tzu W, Matthew P. World Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends: Alzheimer's disease international; 2015.
2. Choo LP, Wetzel DL, Halliday WC, Jackson M, LeVine SM, Mantsch HH. In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. *Biophys J*. 1996; 71:1672–9.
3. Devitt G, Howard K, Mudher A, Mahajan S. Raman Spectroscopy: An emerging tool in neurodegenerative disease research and diagnosis. *ACS Chem Neurosci*. 2018;9:404–420. <https://doi.org/10.1021/acscchemneuro.7b00413>.
4. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. *Nat Med*. 2014;20:415–8.
5. Azria D, Blanquer S, Verdier J-M, Belamie E. Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis. *J Mater Chem B*. 2017;5:7216–37.
6. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid- β biomarkers for Alzheimer's disease. *Nature*. 2018;554:249.
7. Nabers A, Ollesch J, Schartner J, Kötting C, Genius J, Hafermann H, et al. Amyloid- β -secondary structure distribution in cerebrospinal fluid and blood measured by an immuno-infrared-sensor: a biomarker candidate for Alzheimer's disease. *Anal Chem*. 2016;88:2755–62.
8. Paraskevasidi M, Morais CLM, Lima KMG, Snowden JS, Saxon JA, Richardson AMT, et al. Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood. *Proc Natl Acad Sci U S A*. 2017;114:E7929–e38.
9. Jermyn M, Mok K, Mercier J, Desroches J, Pichette J, Saint-Arnaud K, et al. Intraoperative brain cancer detection with Raman spectroscopy in humans. *Sci Transl Med*. 2015;7:274ra19.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

